Early combination therapy for newly diagnosed pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been newly diagnosed with pulmonary arterial hypertension (PAH) within the last 12 weeks, and you have not taken PAH medicines for more than 6 weeks.
- Your diagnosis was confirmed by a right heart catheterization, showing high pressure in the lung arteries.
- You do not have significant lung disease, heart failure, or a history of severe bleeding.
- If you are a woman who could become pregnant, you must agree to use highly effective birth control; if you are a man with a partner who could become pregnant, you must use a condom during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a medication called sotatercept affects the blood vessels in the lungs over time. It aims to see if it can help improve how the heart and lungs work in people with pulmonary hypertension.
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
This trial tests how a new medication, sotatercept, affects the heart and lungs in people with pulmonary arterial hypertension (PAH). Using a special scan, the study looks at how the drug changes the blood vessels and heart over time to see if it helps.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.